Genmab reported DKK1.93B in Operating Profit for its third fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Operating Profit Change
Agios Pharmaceuticals AGIO:US USD -86647000 8.29M
Amarin AMRN:US USD -5144000 57.69M
Amgen AMGN:US USD 2.74B 562M
Artemis Alpha ATS:LN GBP -26696000 16.49M
AstraZeneca AZN:LN USD 1.25B 706M
Bayer BAYN:GR EUR 1.2B 1.03B
Biomarin Pharmaceutical BMRN:US USD -2417000 41.57M
Bluebird Bio BLUE:US USD -84781000 22.62M
Exelixis EXEL:US USD 82.61M 1.09M
Fresenius Medical Care FME:GR EUR 472M 131M
Galapagos GLPG:NA EUR -37578000 38.75M
Genmab GEN:DC DKK 1.93B 684M
GlaxoSmithKline GSK:LN GBP 1.19B 110M
Hikma Pharmaceutical HIK:LN USD 249M 6M
Immunogen IMGN:US USD -77429000 16.38M
Insmed INSM:US USD -127697000 39.38M
Lonza Group LONN:SW CHF 645M 111M
Merck MRK:GR EUR 1.23B 57M
Novartis NOVN:VX USD 2.17B 60M
Regeneron Pharmaceuticals REGN:US USD 1.22B 113.8M
Seattle Genetics SGEN:US USD -192805000 59.69M
William Demant Holding WDH:DC DKK 1.59B 219M